Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis Volume 8, 2007 - Issue 6
Journal homepage
171
Views
15
CrossRef citations to date
0
Altmetric
Original Article

Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects

Srikanth Ranganathan Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, MD, USA
,
Georgina C. B. Nicholl Departments of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
,
Sarah Henry Departments of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
,
Fran Lutka Departments of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
,
Ramasri Sathanoori Lofstrand Labs Limited, Gaithersburg, MD, USA
,
David Lacomis Departments of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
&
Robert Bowser Departments of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USACorrespondence[email protected]
 show all
Pages 373-379 | Received 31 Jan 2007, Accepted 25 Jun 2007, Published online: 10 Jul 2009

References

  • Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004; 1: 189–95
  • Coon K. D., Dunckley T., Stephan D. A. Biomarker identification in neurologic diseases: improving diagnostics and therapeutics. Expert Rev Mol Diagn 2004; 4: 361–75
  • Bowser R., Cudkowicz M., Kaddurah‐Daouk R. Biomarkers for amyotrophic lateral sclerosis. Expert Rev Mol Diagn 2006; 6: 387–98
  • Miller D. H. Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx 2004; 1: 284–94
  • Puchades M., Hansson S. F., Nilsson C. L., Andreasen N., Blennow K., Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Mol Brain Res 2003; 118: 140–6
  • Carrette O., Demalte I., Scherl A., Yalkinoglu O., Corthals G., Burkhard P., et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003; 3: 1486–94
  • Ranganathan S., Williams E., Ganchev P., Gopalakrishnan V., Lacomis D., Urbinelli L., et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 2005; 95: 1461–71
  • Ferrante R. J., Browne S. E., Shinobu L. A., Bowling A. C., Baik M. J., MacGarvey U., et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997; 69: 2064–74
  • Quinn J. F., Montine K. S., Moore M., Morrow J. D., Kaye J. A., Montine T. J. Suppression of longitudinal increase in CSF F2‐isoprostanes in Alzheimer's disease. J Alzheimer's Dis 2004; 6: 93–7
  • Brettschneider J., Petzold A., Submuth S. D., Ludolph A. C., Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006; 66: 852–6
  • Lescuyer P., Allard L., Zimmerman‐Ivol C. G., Burgess J. A., Hughes‐Frutiger S., Burkhard P. R., et al. Identification of post mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration. Proteomics 2004; 4: 2234–41
  • Finehout E. J., Franck Z., Relkin N., Lee K. H. Proteomic analysis of cerebrospinal fluid changes related to post mortem interval. Clin Chem 2006; 52: 1906–13
  • You J‐S., Gelfanova V., Knierman M. D., Witzmann F. A., Wang M., Hale J. E. The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 2005; 5: 290–6
  • Ranganathan S., Polshyna A., Nicholl G., Lyons‐Weiler J., Bowser R. Assessment of protein stability in cerebrospinal fluid using surface‐enhanced laser desorption/ionization time‐of‐flight mass spectrometry protein profiling. Clin Proteomics 2006; 2: 91–102
  • Brooks B. R., Miller R. G., Swash M., Munsat T. L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lat Scler 2000; 1: 293–9
  • Pasinetti G. M., Ungar L. H., Lange D. J., Yemul S., Deng H., Yuan X., et al. Identification of potential CSF biomarkers in ALS. Neurology 2006; 66: 1218–22
  • Serot J. M., Christmann D., Dubost T., Couturier M. Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 1997; 63: 506–8
  • Biroccio A., del Boccio P., Panella M., Bernardini S., Dillio C., Gambi D., et al. Differential post‐translational modifications of transthyretin in Alzheimer's disease: a study of the cerebral spinal fluid. Proteomics 2006; 6: 2305–13

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.